Medical Center Intermedica Ltd.

Running trials

• Recruiting

  Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics

  2024-519836-18-00· Phase 3· Source

• Enrolling by invitation

  An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

  NCT07161700· Phase 2· Source

• Recruiting

  A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT07196501· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

  NCT07065240· Phase 2· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Source

• Recruiting

  Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06966401· Phase 3· Source

• Recruiting

  Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

  NCT06830044· Phase 3· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

  NCT06651567· Phase 2· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Source

• Recruiting

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Phase 3· Source

• Active, not recruiting

  HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

  NCT05636176· Phase 3· Source

• Recruiting

  Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  NCT05850689· Phase 3· Source

• Recruiting

  A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLUTION study)

  2023-507372-42-00· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression6 recruiting
• Alzheimer disease2 recruiting
• Heart failure2 recruiting
• Schizophrenia2 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

  NCT04521478· Phase 2· Source